Tag: STAT+

STAT+: Beyond statins, one drug lowered heart attack risk by 20%

Health & well-being news
When statins aren’t enough, other cholesterol-lowering drugs come into play. But which one is most effective?Cardiologists looking to help...

STAT+: In China, a flood of controversial clinical trials slows to a trickle 

Health & well-being news
SHANGHAI — Juan Huang noticed her 13-year-old daughter, Huangxi, was leaning out of her stroller, so she undid the...

STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill

Health & well-being news
WASHINGTON – Democrats’ landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a...

STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more

Health & well-being news
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember...

STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test

Health & well-being news
The French pharma Servier said Tuesday that an experimental drug it purchased in June for $1.55 billion in cash,...

STAT+: Pharmalittle: We’re reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more

Health & well-being news
Top of the morning to you. And a fine one it is here at the Pharmalot campus, where the...

STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries

Health & well-being news
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is...

STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more

Health & well-being news
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because...

STAT+: Up and down the ladder: The latest comings and goings

Health & well-being news
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is...

STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more

Health & well-being news
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is,...

STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptides

Health & well-being news
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and...

STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more

Health & well-being news
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an...